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ABSTRACT
Chemotherapy-induced peripheral neuropathy (CIPN) is a type of neuropathic 
pain that represents a frequent and serious consequence of chemotherapy agents.  
Over the last years, significant progress has been achieved in elucidating the 
underlying pathogenesis of CIPN. The interference of taxanes with microtubule  has 
been proposed as a mechanism that leads to altered axonal transport and to permanent 
neurological damages. The inflammatory process activated by chemotherapeutic 
agents has been considered as a potential trigger of nociceptive process in CIPN.
In this study we investigated the effect of reparixin, an inhibitor of CXCR1/
CXCR2, in suppressing the development of paclitaxel-induced nociception in rats. 
Moreover, reparixin activity in reversing the neurotoxic effects induced by paclitaxel 
or GRO/KC in F11 cells was also analyzed.
Reparixin administered by continuous infusion ameliorated paclitaxel-induced 
mechanical and cold allodynia in rats. In F11 cells, reparixin was able to inhibit 
the increase of acetyladed α-tubulin induced both by paclitaxel and GRO/KC. The 
subsequent experiments were performed in order to dissect the signal transduction 
pathways under GRO/KC control, eventually modulated by paclitaxel and/or reparixin. 
To this aim we found that reparixin significantly counteracted p-FAK, p-JAK2/p-STAT3, 
and PI3K-p-cortactin activation induced either by paclitaxel or GRO/KC.
Overall the present results have identified IL-8/CXCR1/2 pathway as a mechanism 
involved in paclitaxel-induced peripheral neuropathy. In particular, the obtained data 
suggest that the inhibition of CXCR1/2 combined with standard taxane therapy, in 
addition to potentiating the taxane anti-tumor activity can reduce chemotherapy-
induced neurotoxicity, thus giving some insight for the development of novel treatments.
INTRODUCTION
Chemotherapy-induced peripheral neuropathy 
(CIPN) is a common and potentially disabling side 
effect of many anticancer drugs [1]. The most frequent 
symptoms are pain, numbness, or tingling in the hands 
or feet [1–2]. In a recent meta-analysis of several studies 
involving 4179 patients on various chemotherapeutic 
regimens, the prevalence of CIPN was 68.1% within the 
first month of treatment, 60.0% at 3 months, and 30.0% 
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at 6 months [3]. With such a high prevalence of disease, 
CIPN has important clinical implications significantly 
impacting the quality of life and often resulting in 
treatment discontinuation, which may ultimately affect 
overall survival [4, 2]. Despite the intensive research 
dedicated to the identification of therapeutic options able 
to prevent or treat CIPN [5], the medical need remains 
very high.
The pathogenesis of CIPN has not been fully 
elucidated but it is noteworthy that the overall neuropathy 
symptom profile appears to be substantially shared 
across different classes of chemotherapeutic agents 
including taxanes, platinum, proteasome inhibitors, and 
vinca-alkaloids. Peripheral nerve degeneration or small 
fiber neuropathy is generally accepted as the underlying 
mechanism in the development of CIPN [6–7] but 
several studies point out that neuropathic pain caused by 
anticancer agents may occur early after the first infusion 
in the absence of damage to intra-epidermal nerve fibers or 
axonal degeneration in peripheral nerves [8–9].
Microtubule-stabilizing agents (MTSAs), including 
taxanes, are effective chemotherapeutic agents for the 
treatment of many oncologic conditions [10]. Although 
it is clear that chemotherapeutic agents that damage 
microtubules, interrupt mitochondrial function, or directly 
target DNA may affect the integrity and functionality 
of axons thus leading to peripheral nerve degeneration, 
several preclinical and clinical evidences concur to suggest 
a common physio-pathological mechanism partially 
independent from the antineoplastic drug  molecular target. 
The inflammatory process activated by 
chemotherapeutic agents has been considered a potential 
trigger of the nociceptive process in CIPN [11–12] and 
the chemotherapy-driven release of proinflammatory and 
chemotactic cytokines (chemokines) has been identified 
as one of the primary mechanisms regulating the neuro-
immune communication. 
Chemotherapeutic exposure consistently induces 
production and release of pro-inflammatory cytokines 
such as TNF-α , IL-1β, IL-6  and chemokines such as IL-8 
and MCP-1 [13–15]. 
Pro-inflammatory cytokines can contribute to 
neural damage not only by activating the inflammatory 
process but also by a direct receptor-mediated activity on 
neurons and glial cells [16–20]. Among the chemokines, 
Il-8 and its receptors CXCR1/2 have been shown to 
be upregulated in several animal models following 
nerve injury and implicated in the development and 
maintenance of neuropathic pain and of the inflammatory 
hypernociception [21–22].
Interestingly, in a recent controlled study in patients 
with painful peripheral neuropathy, IL-6 and IL-8 gene 
expression were found significantly up-regulated in the 
affected skin biopsies [23] prompting a strong interest on 
these mediators as potential pharmacological targets for 
pain management.
The chemokine effects on pain sensation are 
complex and additional effort is required to clarify the 
role of these mediators in cancer derived algesia; only 
the identification of potent and selective chemokine 
clinical grade inhibitors will allow to fully understand the 
therapeutic potential of this approach. 
Reparixin is an investigational, non-competitive 
allosteric inhibitor of the IL-8 receptors CXCR1 and 
CXCR2 [24] and it has been investigated as a potential 
novel antineoplastic agent in synergy with standard 
chemotherapy targeting the CXCR1+ breast cancer stem 
population [25–27]. In a recently completed phase Ib trial 
in metastatic breast cancer, the safety, pharmacokinetics 
and antitumor activity of reparixin in combination with 
weekly paclitaxel were investigated. In this study we 
observed a sizeable response rate with a low incidence 
and severity of peripheral neuropathy, suggesting that 
neurological toxicity, but not antitumor activity, may be 
reduced by reparixin administration [26]. 
In this paper we put to test for the first time the 
hypothesis that inhibition of IL-8 signaling could attenuate 
the development of chemotherapy induced neurotoxicity. 
On these bases, this work aimed to clarify the effect 
of paclitaxel on CXCR1-CXCR2 dependent pathways in 
neuropathic pain and to elucidate the effect of a known 
CXCR1-CXCR2 inhibitor, reparixin, in counteracting 
neuropathic pain behavior and biomarkers in the CIPN 
context.
RESULTS
In vivo model: effect of reparixin in paclitaxel-
induced mechanical and cold allodynia 
In control animals administered with paclitaxel 
vehicle i.p., the paw withdrawal threshold remained 
unchanged during the whole experimental period, with 
a trend corresponding to that achieved in naïve animals 
with received no treatment (data not shown). In contrast, 
paclitaxel-saline -treated animals showed marked changes 
in paw withdrawal responses, which are prominently 
displayed at 5 days after the first paclitaxel treatment (the 
first time point observation after paclitaxel injection) and 
persisted at least 2 weeks (Figure 1A).
In particular, in DPA test, paw withdrawal threshold 
of paclitaxel-saline-treated animals resulted significantly 
reduced at day 5, 7, 10 and 14 (Figure 1A). Similarly, in 
cold allodynia experiments, no paw withdrawal response 
was induced by acetone in control  animals, indicating 
that acetone-evoked cold stimulation is not noxious in 
non neurophatic rats. On the other hand, the numbers of 
paw withdrawal threshold resulted significantly increased 
at days 5, 7, 10 and 14, in paclitaxel-saline-treated animals 
(Figure 1B).
Reparixin antinociceptive effect was visible over 
the time-course corresponding to drug delivery by micro-
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osmotic pump; conversely, the activity disappeared after 
the end of drug delivery by pump (day 11), indicating 
that the observed protection is strictly correlated to drug 
administration and action.
In fact, continuous infusion of reparixin (8mg/hr/kg) 
was able to reduce in a significant way, paclitaxel-evoked 
mechanical allodynia at days 5 (P < 0.01), 7 (P < 0.001), and 
10 (P < 0.001), whereas no activity was determined at day 
14, three days after the end of drug delivery  (Figure 1A). 
Likewise, animals treated with reparixin showed a 
significant reduction of cold allodynia at days 5 (P < 0.01), 
7 (P < 0.001), and 10 (P < 0.001), whereas, no activity 
was determined at day 14, three days after the end of drug 
delivery (Figure 1B).
In vitro models
The viability assay under the different treatments 
(Figure 2A) shows that paclitaxel, in the concentration-
range of 5–20 nM, and reparixin, in the concentration 
range of 5–20 µM were ineffective in modulating cells 
viability.
For all the other experiments, reparixin was used at 
the final concentration of 10 µM and paclitaxel at the final 
concentration of 10 nM.
In Figure 2B, control (not treated), paclitaxel and 
reparixin treated neurons probed for anti-acetylated 
α-tubulin (markers of stable microtubules) are shown. 
In control cells, acetylated α-tubulin appears moderately 
present; a similar situation is found in cells treated with 
reparixin. In paclitaxel-treated neurons, in agreement 
with the literature [28], increased acetylated α-tubulin is 
observed. In fact, the fluorescence intensity in neurites 
appears more intense and an increase of neurite diameter 
and cytoskeleton organization is apparent. Acetylated 
α-tubulin in paclitaxel+reparixin-treated neurons appears 
similar to that of control conditions, thus indicating that 
reparixin presence counteracts paclitaxel effects. 
Acetylated α-tubulin was assayed also by western 
blotting analysis. In Figure 2C, the western blotting 
and densitometric analyses for this marker are reported. 
In agreement with the morphological data, paclitaxel 
determines a significant increase of acetylated α-tubulin, 
while under combined treatments the protein appears 
at the same level of control cells. In order to determine 
whether the observed effects may be triggered by the 
CXCR2 natural ligand, GRO/KC, which is thought to 
play a role in the rat similar to that played by IL-8 in 
humans, was used. Acetylated α-tubulin was re-assayed 
by western blotting under GRO/KC treatment at different 
concentrations (Figure 2D), and compared to paclitaxel 
treatment. It is possible to observe that GRO/KC is able to 
increase acetylated α-tubulin at each concentration used. 
The subsequent experiments were performed in order 
to dissect the signal transduction pathways, under GRO/KC 
control, eventually modulated by paclitaxel and/or reparixin 
(Figure 3). To this purpose the first enzyme studied was the 
active form of the protein of fokal adhesion, p-FAK. The 
protein is significantly increased by paclitaxel treatment, 
while under combined treatments it appears at the same 
level of control cells (Figure 3A).
In control and treated cells, the localization for the 
cytoskeletal component actin (Figure 3B) and the SEM 
analysis (Figure 3C) were also performed. By the mean of 
actin localization also neurite thickness (Figure 3D) was 
calculated. It is possible to observe that under paclitaxel 
treatment, neurites appear with a greater thickness than 
control cells. Under combined treatment cells appear as 
control ones.
The other enzyme of CXCR1/CXCR2 pathway 
studied was the active form of the JAK2 protein, involved 
in the p-STAT3 signaling (Figure 4A), which in turn is 
Figure 1: Effect of reparixin on paclitaxel-induced mechanical and cold allodynia: In control animals administered 
with paclitaxel vehicle i.p. (Ctr, black dots) the paw withdrawal responses remained unchanged during the whole experimental period 
(panel A and B). Rats treated with paclitaxel + pumps filled with saline (Pac+Saline, gray dots), showed marked changes in paw withdrawal 
responses (panel A and B).  Continuous infusion of reparixin (Pac+Rpx, light gray dots) was able to reduce in a significant way, paclitaxel-
evoked mechanical (panel A) and cold (panel B) allodynia at days 5, 7 and 10, whereas no activity was determined on day 14, three days 
after the end of drug delivery. Data are shown as mean ± SE of 10 animals per group. ***P < 0.001, and **P < 0.01 vs the respective Ctr 
group; ###P < 0.001 and ##P < 0.01 vs the respective Pac+Saline group. 
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involved in neuropathic pain and synaptic plasticity 
[29–30]. It is possible to observe that paclitaxel increases 
p-JAK2, while the presence of reparixin restores the 
control conditions. In the same Figure 4B, p-STAT3 levels, 
under the different conditions, are reported. Paclitaxel 
increases p-STAT3 levels, with respect to control, while 
reparixin counteracts this effect. 
Finally, PI3K-p-cortactin pathway, which is 
involved in axonal arborization and synaptic plasticity, 
appears strongly up-regulated by paclitaxel, while 
the presence of reparixin counteracts also this effect 
(Figure 4C and 4D).
With the aim to clarify the correlation between 
paclitaxel effects and GRO/KC effects, F11 cells were 
incubated with paclitaxel for 24h and levels of GRO/
KC released into the culture medium were quantitated by 
ELISA assay. The obtained results showed that paclitaxel 
was able to induce a significant increase in GRO/KC 
release (Figure 5). 
The whole CXCR1/CXCR2-mediated pathway was 
re-assayed in the presence of GRO/KC in place of paclitaxel, 
obtaining the same effects of paclitaxel (Figure 5), thus 
indicating that all the effects of taxol in inducing neuropathic 
pain biomarkers are under GRO/KC control.
Finally, the effect of reparixin on GRO/KC-induced 
p-cortactin and p-Fak was tested; in line with the previous 
experimental data, reparixin markedly inhibited both the 
biomarkers (Figure 5F and 5G).
Figure 2: cell viability assay under the different treatments. (A) Control, paclitaxel and reparixin treated neurons probed 
for anti-acetylated α-tubulin are shown (B) In panel (C) the western blotting and densitometric analyses for acetylated α-tubulin are 
reported. In order to determine whether the observed effects may be triggered by the CXCR2 natural ligand, GRO/KC, was used. In panel, 
(D) acetylated α-tubulin was re-assayed by western blotting under GRO/KC treatment at different concentrations, and compared to 
paclitaxel treatment. Data are mean ± SE of 3 different experiments. **p < 0.005; ***p < 0.0005.  Bar = 75 µm.
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DISCUSSION
CIPN is a common and potentially severe adverse 
effect associated with MTSA therapy [31] and taxane-
induced neuropathy is by far the most extensively 
investigated in preclinical and clinical studies. Such a 
neuropathy, usually presenting as sensory neuropathy, 
is more frequently associated with paclitaxel than 
docetaxel and seems to depend on the dose per treatment 
cycle, the schedule of treatment, and the duration of the 
infusion. Despite clinical efforts to minimize paclitaxel-
induced neurotoxicity, no drugs are approved as of today 
to prevent or treat CIPN, which often requires dose 
reduction or treatment interruption with a major impact 
on patients quality of life and clinical outcome [4, 2, 5]. 
Taxanes bind the inner surface along the entire length of 
microtubules promoting their stabilization by suppression 
of microtubule shortening events [32]. In addition to their 
important function in cell division, microtubules play 
an essential role in cell morphology and intracellular 
transport [33]. Accordingly taxane-induced CIPN has been 
for a long time interpreted as a consequence of MTSA 
interference with normal microtubule-dependent axonal 
transport leading to interruption of axoplasmic flow and, 
as a consequence, to damage of peripheral nerves [34].
Along the last decades, great effort has been made 
to further investigate the underlying physiopathological 
mechanisms and additional evidences emerged [9, 35–
38] suggesting several alternative mechanisms [6, 39]. 
Among those, extensive research has been dedicated to 
Figure 3:(A) Western blotting analysis for the active form of the protein of fokal adhesion, p-FAK. In panel (B) the localization 
for the cytoskeletal component actin on control and treated cells is reported. The SEM analysis were also performed and reported in panel 
(C). By the mean of actin localization also neurite thickness was calculated (panel D). Data are mean ± SE of 3 different experiments. 
*p < 0.05; Bar = 25 µm.
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chemotherapy-induced inflammation as the potential 
common driver of CIPN. Several independent studies 
concur to demonstrate a chemotherapy-induced increase of 
peripheral pro-inflammatory and chemoactractant cytokine 
levels and an apparent correlation with behavioral 
toxicities and peripheral neuropathy [11, 40].
Inflammatory cytokines and chemokines (TNFα, 
IL-1β, IL-6, CCL2, IL-8), produced and secreted by 
neurons and by infiltrated macrophages in response to the 
chemotherapy-induced injury, can cause neurotoxicity 
not only by triggering the inflammatory response but 
also by modulating spontaneous nociceptor sensitivity 
and activity [41–42]. The key role of pro-inflammatory 
mediators in the development of CIPN has found 
important confirmations in preclinical studies that proved 
the efficacy of specific IL-1β and TNFα blockage in 
attenuating peripheral neuropathy in relevant animal 
models [16, 28, 43]. 
Chemokine signaling in leukocytes is mediated 
by the specific interaction with membrane receptors that 
belong to the large family of G protein-coupled receptors 
(GPCRs) [44]. Compelling evidence demonstrated that 
chemokine receptors are also expressed in neurons and 
astrocytes and significantly up-regulated during both 
early-phase and late-phase of chronic pain suggesting an 
implication of this pathway in neuroinflammation [45]. 
Among the chemokines family, IL-8 and its 
receptors CXCR1/2 have been emerging as one of 
the most promising target for the pharmacological 
management of CIPN due to its implication in sympathetic 
components of inflammatory hypernociception and in 
neuropathic nociceptive response [46–47]. Interestingly, 
a recent controlled clinical study showed a significant 
upregulation of IL8 gene expression in the skin biopsies 
of patients affected by CIPN [23]. Also, the results of a 
recently completed phase Ib trial in metastatic breast 
Figure 4: Western blotting analysis for the active form of the JAK2 protein, involved in the p-STAT3 signaling (A). In panel 
B, p-STAT3 levels, under the different conditions. In panels (C and D), the pathway PI3K-p-cortactin is reported. Data are mean ± SE of 
3 different experiments. *p <  0.05; **p < 0.005.
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Figure 5: (A) GRO/KC 5 levels released into the culture medium, quantitated by ELISA assay The whole CXCR1/CXCR2-
mediated pathway re-assayed in the presence of GRO/KC in the place of paclitaxel is shown in Panels (B–E). The effects 
of reparixin on GRO/KC-induced p-cortactin and p-Fak is reported in Panels (F and G). Data are mean ± SE of 3 different experiments. 
*p < 0.05; **p < 0.005.
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cancer, showed that combination of reparixin with weekly 
paclitaxel resulted in a sizeable response rate with a 
low incidence and severity of peripheral neuropathy, 
suggesting that taxane-induced neurological toxicity, 
but not antitumor activity, may be reduced by CXCR1/2 
inhibition [27].
Starting from this observation and with the aim to 
dissect molecular mechanisms underlying the effects of 
CXCR1/CXCR2 blocking compounds in counteracting 
initiation and progression of paclitaxel-induced peripheral 
neuropathy, we evaluated direct effects of IL-8-induced 
signaling in DRG derived neurons cultures.
Tubulin acetylation participates the complex process 
regulating microtubule dynamics that is influenced by a 
number of different microtubule-associated proteins 
(MAPs), including the end binding proteins EB1 and EB3 
implicated in the promotion of microtubule growth and 
axonal transport and in linking dynamic microtubules 
with the actin cytoskeleton [48–50]. In our experimental 
conditions, the paclitaxel-induced increase of α-acetylated 
tubulin in DRG derived neurons was efficiently 
counteracted by the presence of reparixin. Reparixin 
effects were also apparent on the signal transduction 
pathways dissected in the study. IL-8 is significantly up-
regulated by paclitaxel in DRG derived neurons. Even 
though the observed expression increase was relatively 
modest, it was sufficient to trigger the activation of IL-8 
signal upon paclitaxel treatment. 
Under paclitaxel treatment DRG derived neurons 
were shown to express higher levels of p-JAK2 which in 
turn activates p-STAT3, known to be involved in neuropathic 
pain and synaptic plasticity [29-30]. Additionally, exposure 
to paclitaxel was shown to increase the active form of 
fokal adhesion kinase (p-FAK), involved in microtubule 
stabilization [51], and to activate the PI3K-p-cortactin 
pathway that ultimately leads to terminal axonal arborization 
and synaptic plasticity [52]. With the aim to confirm the 
hypothesis that paclitaxel-induced neurotoxic effects are 
mainly mediated by IL8, the expression of CXCR2 and the 
effects of GRO/KC treatment on F11 were investigated. 
CXCR2 was found expressed on F11 (data not shown) 
and receptor binding of IL8 triggered the same pathways 
activated by paclitaxel. In agreement with the observed 
in vivo effect, CXCR2 inhibition by reparixin significantly 
counteracted p-STAT3, p-FAK and PI3K-p-cortactin 
activation induced either by paclitaxel or GRO/KC.
In summary, the majority of the effects of paclitaxel 
on DRG derived neurons in culture seem to be mediated 
by the GRO/KC -dependent pathway and blockade of 
GRO/KC receptors by reparixin effectively inhibited 
in vitro and in vivo paclitaxel-induced neurotoxic effects.
In breast cancer models, reparixin showed the 
ability to reduce the CSC population in vitro and in tumor 
xenografts. It is remarkable how the signaling pattern 
activated by paclitaxel/IL8 in F11, putatively responsible 
for neurons sensitization, is largely the same pattern that 
in breast cancer tumor cells was reported to promote tumor 
growth and invasiveness. In a recent paper the effects of 
reparixin on paclitaxel-induced signaling was studied 
in highly purified mammospheres derived from triple 
negative MDA-MB231 breast cancer cells showing that 
its effect in breast cancer cells was mediated by inhibition 
of paclitaxel/GRO/KC-induced p-FAK, p-AKT, p-STAT3 
and β-catenin activation [26]. 
FAK is a cytoplasmic tyrosine kinase identified 
as a key mediator of intracellular signaling by integrins 
involved in the regulation of different cellular functions 
in a variety of cells [53-54]. Consistent with reparixin 
pharmacological effects, p-FAK activation in breast cancer 
cells was previously reported to be implicated in anchorage-
independent growth [55] and in breast cancer tumorigenesis 
and progression [56-60] whereas in sensory neurons β1-
integrin activity and FAK phosphorylation at tyrosine 397 
(FAKpY397) are linked to neuronal polarization as well as 
neurite outgrowth and branching [61].
The avoidance of pFAK activation by CXCR1/2 
inhibition in breast cancer cells results in sensitization 
and reduction of migrative potential of stem cells, while 
the inhibition of the same pathway in peripheral sensory 
neurons, promoted by taxane treatment via exocrine 
and endocrine IL-8 production, may efficiently prevent 
microtubule acetylation, terminal axons arborization and 
synaptic plasticity thus modulating the key features of 
chemotherapy-associated neurotoxicity.
Since the cytotoxic effect of taxanes on cancer 
cells is strictly associated with the ability to stabilize 
microtubules and to promote net microtubule 
polymerization, the effect of reparixin treatment on 
α-tubulin association observed in sensory neurons 
was investigated with the aim to understand potential 
implication on cancer cells biology. 
Biochemically, also in cancer cells paclitaxel 
induces α-tubulin expression and acetylation. While 
tubulin acetylation has historically been viewed as a 
marker but not a cause of microtubule stability, recent 
work suggests an active role of the tubulin acetylation/
deacetylation process in the regulation of cell motility [62-
64]. In particular, the inhibition of tubulin deacetylation 
mediated by two identified tubulin deacetylases HDAC6 
and SIRT2 enhances sensitivity to the anti-motility 
activity of paclitaxel theoretically potentiating the anti-
tumor effect of the drug [65-67]. In this perspective, 
we investigated in this paper the effect of paclitaxel on 
α-tubulin acetylation, the outcome of reparixin inhibition 
on paclitaxel-induced tubulin acetylation in MDA-
MB231-derived breast cancer stem tumorspheres. The 
evidence that reparixin did not inhibit paclitaxel-induced 
tubulin acetylation in MDA-MB231 is coherent with the 
reported synergic effect of reparixin and paclitaxel on 
breast cancer cell survival, motility and invasiveness. The 
apparently divergent effect of reparixin combination on 
neural and cancer cells functionality is coherent with the 
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specific pathways activated by CXCR1/2 receptors in the 
two different cellular contexts.  
Overall the results described in this paper for the 
first time provide evidences that IL-8 and its receptors 
CXCR1/2 play a key role in the induction and progression 
of peripheral neuropathy and  reinforce the hypothesis 
that CXCR1/2 inhibitors combined with standard taxane 
therapy might potentiate the taxane anti-tumor activity 
and reduce the chemotherapy-induced neurotoxicity. Since 
JAK2, STAT3 and PI3K pathways are also involved in 
several other activities such as apoptosis and senescence, 
that are two phenomena that could be induced by 
anticancer drugs, future investigations will be performed 
in order to evaluate if treatment with reparixin may have 
any effect on these phenomena as already described by 
other Authors in different cancer cells [68–70]. 
MATERIALS AND METHODS
In vivo model
Animals 
The behavioral experiments were performed on 
male Wistar rats (200-250 g, Harlan Italy) housed in 
the animal care facility of the Department of Pharmacy 
of the University of Naples Federico II, Italy. Animals 
were housed in a room with controlled temperature 
(22±1 °C), humidity (60 ± 10%) and light (12 h per day); 
food and water were available ad libitum. All behavioral 
tests were performed between 9:00 AM and 5:00 PM, 
and the animals were used only once. Animal care and 
manipulations were conducted in conformity with 
International and National law and policies (EU Directive 
2010/63/EU for animal experiments, ARRIVE guidelines 
and the Basel declaration including the 3R concept). The 
procedure reported here were approved by the Institutional 
Committee on the Ethics of Animal Experiments (CVS) 
of the University of Naples Federico II and by Ministero 
della Salute under protocol n. 2014-00884607. Ten 
animals per group were used.
Drug treatment
Reparixin L-lysine salt was administered by 
continuous infusion at the effective dose of 8mg/hr/
kg [71] using micro-osmotic pumps (ALZET Model 
2ML2 Charles River). Alzet model 2ML2 pump has an 
approximate 2ml reservoir that delivers a preloaded drug 
or vehicle solutions continuously for 14 days at a rate 
of 5 µl/h. Pumps were filled with reparixin L-lysine salt 
dissolved in sterile saline at a concentration of 375 mg/ml 
according to the instruction of the supplier. Briefly, pumps 
were filled with 2 ml of reparixin solution or vehicle 
(saline) using sterile syringe. Finally, pumps were kept in 
water bath overnight in stove at 37°C.
Surgical implantation of osmotic pumps
Osmotic pumps were implanted under 
intraperitoneal (i.p.) anesthesia (100 mg/kg ketamine 
and 10 mg/kg xylazine). The osmotic pump was inserted 
through a surgical incision made on the back. Briefly, 
a small incision was made in the skin between the 
scapulae and a pocket was formed by spreading apart 
the subcutaneous connective tissues. The pump was 
inserted into the pocket with the flow moderator pointing 
away from the incision. Finally the incision was sutured 
and closed with sutures. Pumps were implanted 3 days 
before paclitaxel injection (day -3). The cessation of drug 
delivery was expected at day +11, as represented in the 
below scheme, since the duration of administration of 
2ML2 mini pumps is 2 weeks.
Induction of neuropathy by paclitaxel
Rats received four once daily i.p. injections of 
paclitaxel (2 mg/kg/day; cumulative dose of 8 mg/kg; 
Tocris, Italy) or vehicle (15% PEG400, 5% Tween80 
and saline, 1ml/kg/day), administered on alternate days 
(day 0, 2, 4, and 6) as described [9]. Behavioral testing 
was performed prior to paclitaxel/vehicle administration 
(day -1) in order to determine the basal values of the 
mechanical and cold nociceptive thresholds, and again on 
day 5-7-10-14 following paclitaxel/vehicle injection. as 
shown in the scheme above.
Mechanical allodynia
To assess for changes in sensation or in the 
development of mechanical allodynia, sensitivity to 
tactile stimulation was measured using the Dynamic 
Plantar Aesthesiometer (DPA, Ugo Basile, Italy), which 
is an automated version of the von Frey hair assessment 
[72]. Individual animals were placed in Plexiglas boxes 
(30× 30× 25 cm) with a mesh metal floor covered by a 
plastic dome that enabled the animal to walk freely, but 
not to jump. When a trial is initiated, the device raises 
the filament to touch the foot and progressively increases 
force until the animal withdraws its foot, or until it 
reaches a maximum of 50 g of force (cut-off). The DPA 
automatically records the force at which the foot is 
withdrawn. This test does not require any special pre-
training, just an acclimation period to the environment 
and testing procedure.  Each paw was tested twice per 
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session and the test was performed on both paws on day 
before (day -1) paclitaxel or vehicle first administration 
and then on 5th, 7th, 10th and 14th days after paclitaxel 
or vehicle first administration. No consistent left and 
right differences were observed. The means of the paws 
withdrawal (expressed in gram) were calculated from an 
average of four separate measures. 
Cold allodynia 
Cold sensitivity was measured as the number of 
foot withdrawal responses after application of acetone to 
the dorsal surface of the paw [9; 73]. Individual animals 
were placed in Plexiglas boxes (30× 30× 25 cm). A drop 
of acetone (25 µL) was applied to the dorsal surface of 
paws with a syringe connected to a thin polyethylene tube 
while the rats was standing on a metal mesh. A brisk foot 
withdrawal response, after the spread of acetone over the 
dorsal surface of the paw, was considered as a sign of 
cold allodynia. The procedure was repeated three times 
at 5 minutes intervals on both paws. The mean of the paw 
withdrawal (expressed in number) was determined from 
an average of six separate measures. Cold responses were 
measured before paclitaxel or vehicle first administration 
(day -1) and then on 5th, 7th, 10th and 14th days after. No 
consistent left and right differences were observed. 
In vitro models
Cell culture and treatments
The F11 hybridoma  cells (ECACC 08062601), 
chosen as model of dorsal root ganglion (DRG) neurons 
[74-75] were cultivated in DMEM (Euroclone, MI, Italy) 
medium supplemented with 10% FBS (Sigma-Aldrich St. 
Louis, CO, USA), 1% penicillin/streptomycin (Euroclone) 
and 1% glutamine (Euroclone) at 37°C, in a humidified 
95% air-5% CO2 atmosphere. For all the experiments 
cells were used at 18th passage. For immunofluorescence 
analysis cells were seeded on coverslips at 1 × 104 
cells/cm2 for 24h. After, cells were differentiated with 
mouse NGF (mNGF) (from Dompé farmaceutici S.p.A., 
L’Aquila, Italy). mNGF was dissolved in DMEM with 1% 
penicillin/streptomycin and 1% glutamine (FBS free) at 
the final concentration 50 ng/ml. Medium was replaced 
every 3 days until complete differentiation, that happened 
after 7 days. 
Following neuronal differentiation, neurons were 
treated for 24 hours with reparixin (Dompé farmaceutici 
S.p.A.; 10 µM final concentration), paclitaxel (Sigma-
Aldrich; 10 nM final concentration) and the combination 
of the two molecules.
Reparixin stock solution (53mM) was prepared 
freshly dissolving 7,5 mg of reparixin in 0,5 ml of 
Phosphate Buffer in addition to 5 µl NaOH. Paclitaxel 
stocks solution (10 mM) was prepared dissolving the 
powder in DMSO and aliquots were stored at −20°C. 
In some experiments, GRO/KC (PeproTech NJ, 
USA) was used (at 50, 20, 10 ng/ml) in comparison to 
paclitaxel. GRO/KC stock solution (0.1 mg/ml) was 
prepared dissolving the powder in 0.1% BSA in PBS; 
aliquots were stored at −20°C.
MTS assay
Cell viability was determined at 24 h using Cell 
Titer One Solution Cell Proliferation Assay (Promega 
Corporation Madison, WI, USA) a colorimetric 
method based on 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenil)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS). The quantity of formazan formed, as a function of 
viability, was measured at 492 nm using an ELISA plate 
reader, Infinite F200 (Tecan, Männedorf, Swiss). The 
assay was performed in quintuplicate. The results were 
expressed as absorbance at 492 nm. 
Immunofluorescence
Cells were fixed in 4% paraformaldehyde in PBS 
for 20 min at room temperature (RT) and permeabilized in 
methanol for 5 min at -20°C. Cells were then blocked with 
PBS containing 4% BSA for 30 min and incubated with 
the following primary antibodies diluted in the blocking 
solution overnight at 4°C: rabbit ß-tubulin (Abcam, 
Cambridge, UK ) 1:200; mouse α-tubulin (Abcam) 
1:1000; mouse acetylated α-tubulin (Abcam) 1:500. Cells 
were then rinsed in PBS several times before incubation 
with secondary antibodies, goat anti rabbit conjugated 
with Alexafluor 633 (1:2000), goat anti mouse conjugated 
with Alexafluor 488 (1:2000), (Life Technologies, 
CA, USA) for 30 min at RT. After extensive washing, 
coverslips were mounted with Vectashield mounting 
medium with DAPI (Vector Laboratories Burlingame, 
CA, USA) and then observed at a Leica TCS SP5 confocal 
microscope (Mannheim, Germany).
Phalloidin staining
Cells were fixed in 4% paraformaldehyde in PBS 
for 10 min at RT and permeabilized in TritonX100 0.1% 
for 5 min at −20°C. Cells were incubated overnight at 4°C 
with Phalloidin-FITCH (5mg/ml; Sigma-Aldrich) diluted 
in PBS. After extensive washing with PBS, coverslips 
were mounted with Vectashield mounting medium with 
DAPI (Vector Laboratories Burlingame, CA, USA) and 
then observed at confocal laser microscope.
Neurite thickness
Neurite thickness was analyzed by ImageJ software 
by converting pixels related to single neurite in μm. For 
each neurite at least 3 different measurements at different 
levels were averaged. For each treatment at least 5 fields 
were counted.
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Western blotting
Control and treated cells were collected and lysated 
in ice-cold RIPA buffer (phosphate buffer saline pH 7.4 
containing 0.5% sodium deoxycolate, 1% Nonidet P-40, 
0.1% SDS, 5mM EDTA, 1% protease and phosphatase 
inhibitor cocktails, Sigma). Protein lysates (30 µg; 15 
µg only for acetylated α-tubulin) were separated on 
7–10% SDS–polyacrilamide gel and electroblotted 
onto polyvinyldifluoride membrane (PVDF; Sigma). 
Nonspecific binding sites were blocked by 5% non-fat dry 
milk (Bio-Rad Laboratories, Hercules, CA) in Tris buffered 
saline (TBS: 20mMTris– HCl, pH 7,4, containing 150 mM 
NaCl) for 30 min at RT. Membranes were then incubated 
overnight at 4°C with the following primary antibodies, 
diluted with TBS containing 0,1% Tween 20 (TBS-T) and 
5% non-fat dry milk: mouse acetylated α-tubulin 1:1000 
(Abcam), rabbit p-FAK 1:500 (Santa Cruz), rabbit p-JAK2 
1:500 (Santa Cruz), rabbit PI3K 1:500 (Abcam), pCortactin 
(1:1000) (Abcam), rabbit GAPDH 1:5000 (Santa Cruz), 
goat pSTAT3 1:200 (Santa Cruz). As secondary antibodies, 
peroxidase conjugated anti-rabbit or anti mouse IgG 
(1:1000; Vector Laboratories, Burlingame, CA) and anti-
goat (1:10000 Santa Cruz) were used. Immunoreactive 
bands were visualized by ECL (Pierce), according to the 
manufacturer’s instructions. The relative densities of the 
immunoreactive bands were determinated and normalizated 
with respect to GAPDH , using ImageJ software. Values 
were given as relative units (RU).
Scanning electron microscopy analysis
For Scanning Electron Microscopy (SEM) 
observations, cells were cultured at a density of 10.000 
cells/cm2 on a round cover slip in a 4 well plate and treated 
with paclitaxel, reparixin or reparixin in combination 
with paclitaxel for 24 h. The morphology of the F11 
cells was observed using scanning electron microscope 
(SEM Philips XL-30 CP). The cells were fixed with 
3% glutaraldehyde in PBS at RT for 20 min and then 
washed three times in PBS. Subsequently, the cells were 
dehydrated in graded series of cold ethanol (30, 50, 70, 
85, 90, 95 and 100%; 5 min, two times each). Dehydrated 
samples were dried further in a critical point dryer and 
coated with gold (10 nm) before analysis. 
Quantitation of GRO/KC
The quantification of GRO/KC released in the 
medium was performed using ELISA (enzyme-linked 
immunosorbent assay) kit (Thermo Fisher Scientific 
Waltham, MA, USA) using a microplate reader Infinite 
F200 (Tecan). Briefly, a target-specific antibody had been 
pre-coated in the wells of the supplied microplate, samples 
and standards were then added into these wells and bind 
to the immobilized (capture) antibody. The sandwich was 
formed by the addition of the second (detector) antibody, 
binding to the target on a different epitope from the capture 
antibody. A conjugated enzyme had been incorporated 
into the assay. After incubation periods and wash steps 
to remove unbound antibody from the plate, a substrate 
solution was added reacting with the enzyme-antibody-
target complex to produce measurable signal, measured 
at 450 nm using an ELISA plate reader. The intensity of 
this signal was proportional to the concentration of target 
present in the sample and the results were expressed in 
pg/ml. All ELISA assays were performed in quintuplicate.
Statistics
For the in vivo results, all data were presented as 
the mean ± SE. Analysis of data was conducted using 
GraphPad Prism (GraphPad Software Inc., San Diego, 
CA). The significance of differences between groups was 
determined by two-way analysis of variance (ANOVA) 
followed by Bonferroni post hoc tests for multiple 
comparisons. The level of significance was set at P < 0.05.
For the in vitro results, data were expressed as mean 
± SE. Statistical analysis was performed by the analysis 
of variance (ANOVA) followed by Scheffe’s post hoc test 
analysis. The level of significance was set at P < 0.05 . 
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